187 related articles for article (PubMed ID: 26731191)
1. Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial.
Polyak CS; Yuhas K; Singa B; Khaemba M; Walson J; Richardson BA; John-Stewart G
PLoS Med; 2016 Jan; 13(1):e1001934. PubMed ID: 26731191
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal effect of CD4 by cotrimoxazole use on malaria incidence among HIV-infected Ugandan adults on antiretroviral therapy: a randomized controlled study.
Kasirye R; Grosskurth H; Munderi P; Levin J; Anywaine Z; Nunn A; Kamali A; Baisley K
Malar J; 2016 Jul; 15():361. PubMed ID: 27417903
[TBL] [Abstract][Full Text] [Related]
3. Malaria Parasitemia and Parasite Density in Antiretroviral-Treated HIV-Infected Adults Following Discontinuation of Cotrimoxazole Prophylaxis.
Ottichilo RK; Polyak CS; Guyah B; Singa B; Nyataya J; Yuhas K; John-Stewart G; Waitumbi JN
J Infect Dis; 2017 Jan; 215(1):88-94. PubMed ID: 28077587
[TBL] [Abstract][Full Text] [Related]
4. Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy: a randomised, placebo-controlled study.
Kasirye RP; Baisley K; Munderi P; Levin J; Anywaine Z; Nunn A; Kamali A; Grosskurth H
AIDS; 2016 Feb; 30(4):635-44. PubMed ID: 26558729
[TBL] [Abstract][Full Text] [Related]
5. TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial.
Laurens MB; Mungwira RG; Nyirenda OM; Divala TH; Kanjala M; Muwalo F; Mkandawire FA; Tsirizani L; Nyangulu W; Mwinjiwa E; Taylor TE; Mallewa J; Blackwelder WC; Plowe CV; Laufer MK; van Oosterhout JJ
Trials; 2016 Jul; 17(1):322. PubMed ID: 27431995
[TBL] [Abstract][Full Text] [Related]
6. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study.
Mermin J; Ekwaru JP; Liechty CA; Were W; Downing R; Ransom R; Weidle P; Lule J; Coutinho A; Solberg P
Lancet; 2006 Apr; 367(9518):1256-61. PubMed ID: 16631881
[TBL] [Abstract][Full Text] [Related]
7. The prevalence and antifolate drug resistance profiles of Plasmodium falciparum in study participants randomized to discontinue or continue cotrimoxazole prophylaxis.
Juma DW; Muiruri P; Yuhas K; John-Stewart G; Ottichilo R; Waitumbi J; Singa B; Polyak C; Kamau E
PLoS Negl Trop Dis; 2019 Mar; 13(3):e0007223. PubMed ID: 30897090
[TBL] [Abstract][Full Text] [Related]
8. Increased malaria parasitaemia among adults living with HIV who have discontinued cotrimoxazole prophylaxis in Kitgum district, Uganda.
Orishaba P; Kalyango JN; Byakika-Kibwika P; Arinaitwe E; Wandera B; Katairo T; Muzeyi W; Nansikombi HT; Nakato A; Mutabazi T; Kamya MR; Dorsey G; Nankabirwa JI
PLoS One; 2020; 15(11):e0240838. PubMed ID: 33175844
[TBL] [Abstract][Full Text] [Related]
9. Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-infected women receiving cotrimoxazole prophylaxis: a multicenter randomized placebo-controlled trial.
González R; Desai M; Macete E; Ouma P; Kakolwa MA; Abdulla S; Aponte JJ; Bulo H; Kabanywanyi AM; Katana A; Maculuve S; Mayor A; Nhacolo A; Otieno K; Pahlavan G; Rupérez M; Sevene E; Slutsker L; Vala A; Williamsom J; Menéndez C
PLoS Med; 2014 Sep; 11(9):e1001735. PubMed ID: 25247995
[TBL] [Abstract][Full Text] [Related]
10. Effect of cotrimoxazole prophylaxis on malaria occurrence among HIV-infected adults in West Africa: the MALHIV Study.
Eholié SP; Ello FN; Coffie PA; Héma A; Minta DK; Sawadogo A
Trop Med Int Health; 2017 Sep; 22(9):1186-1195. PubMed ID: 28653454
[TBL] [Abstract][Full Text] [Related]
11. Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP trial): Design.
Anywaine Z; Abaasa A; Levin J; Kasirye R; Kamali A; Grosskurth H; Munderi P; Nunn A
Contemp Clin Trials; 2015 Jul; 43():100-4. PubMed ID: 26009024
[TBL] [Abstract][Full Text] [Related]
12. Co-trimoxazole in addition to antiretroviral therapy may reduce malaria risk in HIV positive adults.
Hawkes N
BMJ; 2016 Jan; 352():i49. PubMed ID: 26738913
[No Abstract] [Full Text] [Related]
13. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea.
Campbell JD; Moore D; Degerman R; Kaharuza F; Were W; Muramuzi E; Odongo G; Wetaka M; Mermin J; Tappero JW
Clin Infect Dis; 2012 Apr; 54(8):1204-11. PubMed ID: 22423133
[TBL] [Abstract][Full Text] [Related]
14. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria.
Jegede FE; Oyeyi TI; Abdulrahman SA; Mbah HA; Badru T; Agbakwuru C; Adedokun O
PLoS One; 2017; 12(3):e0174233. PubMed ID: 28346490
[TBL] [Abstract][Full Text] [Related]
15. Effect of antiretroviral therapy on malaria incidence in HIV-infected Ugandan adults.
Kasirye RP; Grosskurth H; Munderi P; Levin J; Anywaine Z; Nunn A; Kamali A; Baisley K
AIDS; 2017 Feb; 31(4):577-582. PubMed ID: 28121670
[TBL] [Abstract][Full Text] [Related]
16. Effect of cotrimoxazole prophylaxis on the incidence of malaria in HIV-infected children in 2012, in Abidjan, Côte d'Ivoire: a prospective cohort study.
Harouna AM; Amorissani-Folquet M; Eboua FT; Desmonde S; N'Gbeche S; Aka EA; Kouadio K; Kouacou B; Malateste K; Bosse-Amani C; Ahuatchi Coffie P; Leroy V;
BMC Infect Dis; 2015 Aug; 15():317. PubMed ID: 26248711
[TBL] [Abstract][Full Text] [Related]
17. Cotrimoxazole prophylaxis versus mefloquine intermittent preventive treatment to prevent malaria in HIV-infected pregnant women: two randomized controlled trials.
Denoeud-Ndam L; Zannou DM; Fourcade C; Taron-Brocard C; Porcher R; Atadokpede F; Komongui DG; Dossou-Gbete L; Afangnihoun A; Ndam NT; Girard PM; Cot M
J Acquir Immune Defic Syndr; 2014 Feb; 65(2):198-206. PubMed ID: 24220287
[TBL] [Abstract][Full Text] [Related]
18. Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis.
Suthar AB; Vitoria MA; Nagata JM; Anglaret X; Mbori-Ngacha D; Sued O; Kaplan JE; Doherty MC
Lancet HIV; 2015 Apr; 2(4):e137-50. PubMed ID: 26424674
[TBL] [Abstract][Full Text] [Related]
19. Discontinuing cotrimoxazole preventive therapy in HIV-infected adults who are stable on antiretroviral treatment in Uganda (COSTOP): A randomised placebo controlled trial.
Anywaine Z; Levin J; Kasirye R; Lutaakome JK; Abaasa A; Nunn A; Grosskurth H; Munderi P;
PLoS One; 2018; 13(12):e0206907. PubMed ID: 30596666
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.
Bwakura-Dangarembizi M; Kendall L; Bakeera-Kitaka S; Nahirya-Ntege P; Keishanyu R; Nathoo K; Spyer MJ; Kekitiinwa A; Lutaakome J; Mhute T; Kasirye P; Munderi P; Musiime V; Gibb DM; Walker AS; Prendergast AJ
N Engl J Med; 2014 Jan; 370(1):41-53. PubMed ID: 24382064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
